1.Treatment Response and Adverse Reactions in Older Tuberculosis Patients with Immunocompromising Comorbidities.
Seo Yun KIM ; Sang Min LEE ; Jae Joon YIM ; Chul Gyu YOO ; Young Whan KIM ; Sung Koo HAN ; Seok Chul YANG
Yonsei Medical Journal 2013;54(5):1227-1233
PURPOSE: The aim of this study was to elucidate the effects of immunocompromising comorbidities on treatment response and adverse reactions in older tuberculosis (TB) patients. MATERIALS AND METHODS: The medical records of 182 patients older than 65 years with proven TB by positive culture of Mycobacterium tuberculosis and with available drug susceptibility tests were reviewed retrospectively. These patients were subsequently assigned to either the comorbidity group (n=78) or non-comorbidity group (n=104) depending on whether they had immunocompromising comorbidities. RESULTS: The mean durations of treatment were 9.9+/-3.3 months in the comorbidity group and 9.3+/-3.2 months in the non-comorbidity group (p=0.21). M. tuberculosis culture results converted to negative in most patients with available follow-up cultures at two months after treatment. The successful treatment rates were 94.9% and 98.9% in the comorbidity and non-comorbidity groups, respectively (p=0.30). The most common side effects of anti-TB treatment were skin rash/pruritus (13% in the comorbidity group vs. 11% in the non-comorbidity group, p=0.79), gastro-intestinal problems (14% vs. 9%, p=0.25) and hepatotoxicity (14% vs. 7%, p=0.09). CONCLUSION: The present study shows that the successful treatment rate for TB is high and that immunocompromising comorbidities have no effect on the response to treatment and adverse effects in older TB patients.
Age Factors
;
Aged
;
Aged, 80 and over
;
Antitubercular Agents/adverse effects/*therapeutic use
;
Comorbidity
;
Female
;
Humans
;
*Immunocompromised Host
;
Isoniazid/adverse effects/*therapeutic use
;
Male
;
Retrospective Studies
;
Rifampin/adverse effects/*therapeutic use
;
Risk Factors
;
Treatment Outcome
;
Tuberculosis/*drug therapy/epidemiology/immunology
2.Rifampicin-Induced Minimal Change Disease Is Improved after Cessation of Rifampicin without Steroid Therapy.
Dong Hyuk PARK ; Sul A LEE ; Hyeon Joo JEONG ; Tae Hyun YOO ; Shin Wook KANG ; Hyung Jung OH
Yonsei Medical Journal 2015;56(2):582-585
There are several reports to demonstrate that rifampicin, a major anti-tuberculosis agent, is associated with some adverse renal effects, with a few cases of rifampicin-induced minimal change disease (MCD). In the present case, a 68-year-old female presented with nausea, vomiting, foamy urine, general weakness and edema. She had been taking rifampicin for 4 weeks due to pleural tuberculosis. The patient had no proteinuria before the anti-tuberculosis agents were started, but urine tests upon admission showed heavy proteinuria with a 24-h urinary protein of 9.2 g/day, and serum creatinine, albumin, and total cholesterol levels were 1.36 mg/dL, 2.40 g/dL, and 283 mg/dL, respectively. MCD was diagnosed, and the patient achieved complete remission after cessation of rifampicin without undergoing steroid therapy.
Aged
;
Antibiotics, Antitubercular/*adverse effects/therapeutic use
;
Edema/etiology
;
Female
;
Humans
;
Kidney Function Tests
;
Kidney Glomerulus/pathology
;
Nausea/etiology
;
Nephrosis, Lipoid/*chemically induced/pathology
;
Proteinuria
;
Remission Induction
;
Rifampin/*adverse effects/therapeutic use
;
Treatment Outcome
;
Tuberculosis, Pleural/*drug therapy
3.A Case of Pseudomembranous Colitis Associated with Rifampicin Therapy in a Patient with Rectal Cancer and Gastrointestinal Tuberculosis.
Yong Jun CHOI ; Hyung Gil KIM ; Yun Ah CHOI ; Woo Chul JOO ; Dong Wook SON ; Chul Hyun KIM ; Yong Woon SHIN ; Young Soo KIM
The Korean Journal of Gastroenterology 2009;53(1):53-56
Pseudomembranous colitis (PMC) is known to be associated with the administration of antibiotics which alter normal gastrointestinal flora and allow overgrowth of Clostridium difficile. Most cases of rifampicin-induced PMC are seen in patients with pulmonary tuberculosis, but not with gastrointestinal tuberculosis. We report a case of PMC associated with rifampicin therapy in a patient with gastrointestinal tuberculosis. A 65-year-old female patient with rectal cancer and gastrointestinal tuberculosis was admitted due to abdominal pain and diarrhea. She was treated with anti-tuberculosis agents containing rifampicin. On colonoscopic examination, mucoid exudates and yellowish plaque lesions were observed. Anti-tuberculosis agents were stopped, and the patient was treated with metronidazole. Symptoms were relieved and did not recur when all the anti-tuberculosis agents except rifampicin were started again. When a patient complains of abdominal pain or diarrhea while taking rifampicin, the physician should consider the possibility of rifampicin-associated PMC.
Aged
;
Antibiotics, Antitubercular/*adverse effects/therapeutic use
;
Enterocolitis, Pseudomembranous/*diagnosis/etiology/pathology
;
Female
;
Humans
;
Rectal Neoplasms/*complications/diagnosis
;
Rifampin/*adverse effects/therapeutic use
;
Sigmoidoscopy
;
Tuberculosis, Gastrointestinal/complications/diagnosis/*drug therapy
4.Drug-induced Hepatotoxicity of Anti-tuberculosis Drugs and Their Serum Levels.
Ina JEONG ; Jong Sun PARK ; Young Jae CHO ; Ho Il YOON ; Junghan SONG ; Choon Taek LEE ; Jae Ho LEE
Journal of Korean Medical Science 2015;30(2):167-172
The correlation between serum anti-tuberculosis (TB) drug levels and the drug-induced hepatotoxicity (DIH) remains unclear. The purpose of this study was to investigate whether anti-TB DIH is associated with basal serum drug levels. Serum peak levels of isoniazid (INH), rifampicin (RMP), pyrazinamide (PZA), and ethambutol (EMB) were analyzed in blood samples 2 hr after the administration of anti-TB medication. Anti-TB DIH and mild liver function test abnormality were diagnosed on the basis of laboratory and clinical criteria. Serum anti-TB drug levels and other clinical factors were compared between the hepatotoxicity and non-hepatotoxicity groups. A total of 195 TB patients were included in the study, and the data were analyzed retrospectively. Seventeen (8.7%) of the 195 patients showed hepatotoxicity, and the mean aspartate aminotransferase/alanine aminotransferase levels in the hepatotoxicity group were 249/249 IU/L, respectively. Among the 17 patients with hepatotoxicity, 12 showed anti-TB DIH. Ten patients showed PZA-related hepatotoxicity and 2 showed INH- or RMP-related hepatotoxicity. However, intergroup differences in the serum levels of the 4 anti-TB drugs were not statistically significant. Basal serum drug concentration was not associated with the risk anti-TB DIH in patients being treated with the currently recommended doses of first-line anti-TB treatment drugs.
Adolescent
;
Adult
;
Aged
;
Aged, 80 and over
;
Alanine Transaminase/blood
;
Antitubercular Agents/adverse effects/*blood/therapeutic use
;
Aspartate Aminotransferases/blood
;
Drug-Induced Liver Injury/*blood
;
Ethambutol/adverse effects/blood/therapeutic use
;
Female
;
Humans
;
Isoniazid/adverse effects/blood/therapeutic use
;
Liver/*pathology
;
Liver Function Tests
;
Male
;
Middle Aged
;
Pyrazinamide/adverse effects/blood/therapeutic use
;
Retrospective Studies
;
Rifampin/adverse effects/blood/therapeutic use
;
Tuberculosis, Pulmonary/drug therapy
;
Young Adult
5.Drug-induced Hepatotoxicity of Anti-tuberculosis Drugs and Their Serum Levels.
Ina JEONG ; Jong Sun PARK ; Young Jae CHO ; Ho Il YOON ; Junghan SONG ; Choon Taek LEE ; Jae Ho LEE
Journal of Korean Medical Science 2015;30(2):167-172
The correlation between serum anti-tuberculosis (TB) drug levels and the drug-induced hepatotoxicity (DIH) remains unclear. The purpose of this study was to investigate whether anti-TB DIH is associated with basal serum drug levels. Serum peak levels of isoniazid (INH), rifampicin (RMP), pyrazinamide (PZA), and ethambutol (EMB) were analyzed in blood samples 2 hr after the administration of anti-TB medication. Anti-TB DIH and mild liver function test abnormality were diagnosed on the basis of laboratory and clinical criteria. Serum anti-TB drug levels and other clinical factors were compared between the hepatotoxicity and non-hepatotoxicity groups. A total of 195 TB patients were included in the study, and the data were analyzed retrospectively. Seventeen (8.7%) of the 195 patients showed hepatotoxicity, and the mean aspartate aminotransferase/alanine aminotransferase levels in the hepatotoxicity group were 249/249 IU/L, respectively. Among the 17 patients with hepatotoxicity, 12 showed anti-TB DIH. Ten patients showed PZA-related hepatotoxicity and 2 showed INH- or RMP-related hepatotoxicity. However, intergroup differences in the serum levels of the 4 anti-TB drugs were not statistically significant. Basal serum drug concentration was not associated with the risk anti-TB DIH in patients being treated with the currently recommended doses of first-line anti-TB treatment drugs.
Adolescent
;
Adult
;
Aged
;
Aged, 80 and over
;
Alanine Transaminase/blood
;
Antitubercular Agents/adverse effects/*blood/therapeutic use
;
Aspartate Aminotransferases/blood
;
Drug-Induced Liver Injury/*blood
;
Ethambutol/adverse effects/blood/therapeutic use
;
Female
;
Humans
;
Isoniazid/adverse effects/blood/therapeutic use
;
Liver/*pathology
;
Liver Function Tests
;
Male
;
Middle Aged
;
Pyrazinamide/adverse effects/blood/therapeutic use
;
Retrospective Studies
;
Rifampin/adverse effects/blood/therapeutic use
;
Tuberculosis, Pulmonary/drug therapy
;
Young Adult
6.A Sporadic Outbreak of Human Brucellosis in Korea.
Mi Yeoun PARK ; Chang Seop LEE ; Young Sil CHOI ; Seoung Ju PARK ; Joo Sun LEE ; Heung Bum LEE
Journal of Korean Medical Science 2005;20(6):941-946
Eleven cases of human brucellosis occurred among livestock workers and a veterinarian who lived and worked in a rural area around Jeongeup City, Jeollabuk-Do, Korea from February 2003 to August 2003. Eight of the patients had taken care of Korean native cattle that were infected with bovine brucellosis and had already been slaughtered. Two of the patients had taken care of dairy cattle, and one case was a veterinarian who acquired the disease through an accidental contact with infected cattle while assisting in calf delivery. Eleven cases were identified by serologic work ups and four cases were identified via positive blood cultures. This study shows that the Republic of Korea is no longer free of human brucellosis, Brucella abortus biotype 1. We reviewed the patients' characteristics and serologic data during the oneyear follow up period, and we also discuss on the efficacy and side effects of the rifampin and doxycyline regimen used for the treatment of human brucellosis.
Adult
;
Animal Husbandry
;
Animals
;
Anti-Bacterial Agents/adverse effects/therapeutic use
;
Antibodies, Bacterial/blood
;
Base Sequence
;
Brucella abortus/genetics/immunology/isolation and purification
;
Brucellosis/drug therapy/*epidemiology/microbiology/transmission
;
Brucellosis, Bovine/transmission
;
Cattle
;
DNA, Bacterial/genetics
;
Disease Outbreaks
;
Doxycycline/adverse effects/therapeutic use
;
Female
;
Humans
;
Korea/epidemiology
;
Male
;
Middle Aged
;
Occupational Diseases/drug therapy/epidemiology/immunology/microbiology
;
Rifampin/adverse effects/therapeutic use
;
Veterinarians
7.Incidence and Clinical Outcomes of Clostridium difficile Infection after Treatment with Tuberculosis Medication.
Yu Mi LEE ; Kyu Chan HUH ; Soon Man YOON ; Byung Ik JANG ; Jeong Eun SHIN ; Hoon Sup KOO ; Yunho JUNG ; Sae Hee KIM ; Hee Seok MOON ; Seung Woo LEE
Gut and Liver 2016;10(2):250-254
BACKGROUND/AIMS: To determine the incidence and clinical characteristics of tuberculosis (TB) medication-associated Clostridium difficile infection. METHODS: This multicenter study included patients from eight tertiary hospitals enrolled from 2008 to 2013. A retrospective analysis was conducted to identify the clinical features of C. difficile infection in patients who received TB medication. RESULTS: C. difficile infection developed in 54 of the 19,080 patients prescribed TB medication, representing a total incidence of infection of 2.83 cases per 1,000 adults. Fifty-one of the 54 patients (94.4%) were treated with rifampin. The patients were usually treated with oral metronidazole, which produced improvement in 47 of the 54 patients (87%). Twenty-three patients clinically improved with continuous rifampin therapy for C. difficile infection. There were no significant differences in improvement between patients treated continuously (n=21) and patients in whom treatment was discontinued (n=26). CONCLUSIONS: The incidence of C. difficile infection after TB medication was not low considering the relatively low TB medication dosage compared to other antibiotics. It may not be always necessary to discontinue TB medication. Instead, decisions concerning discontinuation of TB medication should be based on TB status.
Adult
;
Aged
;
Aged, 80 and over
;
Anti-Infective Agents/therapeutic use
;
Antibiotics, Antitubercular/*adverse effects
;
*Clostridium difficile
;
Enterocolitis, Pseudomembranous/chemically induced/drug therapy/*epidemiology
;
Female
;
Humans
;
Incidence
;
Male
;
Metronidazole/therapeutic use
;
Middle Aged
;
Retrospective Studies
;
Rifampin/*adverse effects
;
Treatment Outcome
;
Tuberculosis/*drug therapy